Literature DB >> 17582435

The molecular basis for different recognition of substrates by phosphodiesterase families 4 and 10.

Huanchen Wang1, Howard Robinson, Hengming Ke.   

Abstract

Phosphodiesterases (PDEs) are key enzymes that control the cellular concentrations of the second messengers cAMP and cGMP. The mechanism for selective recognition of substrates cAMP and cGMP by individual PDE families remains a puzzle. To understand the mechanism for substrate recognition by PDE enzymes, the crystal structure of the catalytic domain of an inactive D201N mutant of PDE4D2 in complex with substrate cAMP has been determined at 1.56 A resolution. The structure shows that Gln369 forms only one hydrogen bond with the adenine of cAMP. This finding provides experimental evidence against the hypothesis of two hydrogen bonds between the invariant glutamine and the substrate cAMP in PDE4, and thus suggests that the widely circulated "glutamine switch" model is unlikely the mechanism for substrate recognition by PDEs. A structure comparison between PDE4D2-cAMP and PDE10A2-cAMP reveals an anti configuration of cAMP in PDE4D2 but syn in PDE10A2, in addition to different contact patterns of cAMP in these two structures. These observations imply that individual PDE families have their characteristic mechanisms for substrate recognition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17582435      PMCID: PMC2001251          DOI: 10.1016/j.jmb.2007.05.060

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  29 in total

Review 1.  Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.

Authors:  Celine Mehats; Carsten B Andersen; Marcello Filopanti; S L Catherine Jin; Marco Conti
Journal:  Trends Endocrinol Metab       Date:  2002 Jan-Feb       Impact factor: 12.015

2.  A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases.

Authors:  Kam Y J Zhang; Graeme L Card; Yoshihisa Suzuki; D Richard Artis; Daniel Fong; Sam Gillette; Davin Hsieh; Joshua Neiman; Brian L West; Chao Zhang; Michael V Milburn; Sung-Hou Kim; Joseph Schlessinger; Gideon Bollag
Journal:  Mol Cell       Date:  2004-07-23       Impact factor: 17.970

3.  Structural determinants for inhibitor specificity and selectivity in PDE2A using the wheat germ in vitro translation system.

Authors:  André Iffland; Darcy Kohls; Simon Low; Jing Luan; Yan Zhang; Michael Kothe; Qing Cao; Ajith V Kamath; Yuan-Hua Ding; Tom Ellenberger
Journal:  Biochemistry       Date:  2005-06-14       Impact factor: 3.162

Review 4.  Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.

Authors:  Brian J Lipworth
Journal:  Lancet       Date:  2005 Jan 8-14       Impact factor: 79.321

Review 5.  Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside.

Authors:  M C Truss; C G Stief; S Uckert; A J Becker; J Wefer; D Schultheiss; U Jonas
Journal:  World J Urol       Date:  2001-11       Impact factor: 4.226

Review 6.  Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.

Authors:  Y Liu; Y Shakur; M Yoshitake; J Kambayashi Ji
Journal:  Cardiovasc Drug Rev       Date:  2001

Review 7.  Pharmacology of phosphodiesterase-5 inhibitors.

Authors:  J D Corbin; S H Francis
Journal:  Int J Clin Pract       Date:  2002 Jul-Aug       Impact factor: 2.503

8.  Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram.

Authors:  Robert X Xu; Warren J Rocque; Millard H Lambert; Dana E Vanderwall; Michael A Luther; Robert T Nolte
Journal:  J Mol Biol       Date:  2004-03-19       Impact factor: 5.469

Review 9.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

Authors:  Miles D Houslay; David R Adams
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

10.  The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis.

Authors:  Qing Huai; John Colicelli; Hengming Ke
Journal:  Biochemistry       Date:  2003-11-18       Impact factor: 3.162

View more
  13 in total

1.  Computational determination of binding structures and free energies of phosphodiesterase-2 with benzo[1,4]diazepin-2-one derivatives.

Authors:  Bo Yang; Adel Hamza; Guangju Chen; Yan Wang; Chang-Guo Zhan
Journal:  J Phys Chem B       Date:  2010-11-15       Impact factor: 2.991

2.  cUMP hydrolysis by PDE3B.

Authors:  Jessica Ostermeyer; Franziska Golly; Volkhard Kaever; Stefan Dove; Roland Seifert; Erich H Schneider
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-28       Impact factor: 3.000

3.  Insight into binding of phosphodiesterase-9A selective inhibitors by crystal structures and mutagenesis.

Authors:  Huanchen Wang; Xuan Luo; Mengchun Ye; Jing Hou; Howard Robinson; Hengming Ke
Journal:  J Med Chem       Date:  2010-02-25       Impact factor: 7.446

4.  Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays.

Authors:  Ana Santos de Medeiros; Arlene R Wyman; Manal A Alaamery; Christina Allain; F Douglas Ivey; Lili Wang; Hai Le; James P Morken; Alawi Habara; Cuong Le; Shuaiying Cui; Adam Lerner; Charles S Hoffman
Journal:  Cell Signal       Date:  2017-09-01       Impact factor: 4.315

5.  Identification of lead BAY60-7550 analogues as potential inhibitors that utilize the hydrophobic groove in PDE2A: a molecular dynamics simulation study.

Authors:  Jitendra Kumar; Tarana Umar; Tasneem Kausar; Mohammad Mobashir; Shahid M Nayeem; Nasimul Hoda
Journal:  J Mol Model       Date:  2016-12-13       Impact factor: 1.810

6.  Hydrolysis of the non-canonical cyclic nucleotide cUMP by PDE9A: kinetics and binding mode.

Authors:  Jessica Scharrenbroich; Volkhard Kaever; Stefan Dove; Roland Seifert; Erich H Schneider
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-11-15       Impact factor: 3.000

7.  Identification and optimization of PDE10A inhibitors using fragment-based screening by nanocalorimetry and X-ray crystallography.

Authors:  Michael I Recht; Vandana Sridhar; John Badger; Pierre-Yves Bounaud; Cheyenne Logan; Barbara Chie-Leon; Vicki Nienaber; Francisco E Torres
Journal:  J Biomol Screen       Date:  2013-12-27

8.  Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.

Authors:  Alex B Burgin; Olafur T Magnusson; Jasbir Singh; Pam Witte; Bart L Staker; Jon M Bjornsson; Margret Thorsteinsdottir; Sigrun Hrafnsdottir; Timothy Hagen; Alex S Kiselyov; Lance J Stewart; Mark E Gurney
Journal:  Nat Biotechnol       Date:  2009-12-27       Impact factor: 54.908

9.  Structural asymmetry of phosphodiesterase-9, potential protonation of a glutamic acid, and role of the invariant glutamine.

Authors:  Jing Hou; Jie Xu; Ming Liu; Ruizhi Zhao; Hai-Bin Luo; Hengming Ke
Journal:  PLoS One       Date:  2011-03-31       Impact factor: 3.240

10.  cGMP Signaling, Phosphodiesterases and Major Depressive Disorder.

Authors:  Gillian W Reierson; Shuyu Guo; Claudio Mastronardi; Julio Licinio; Ma-Li Wong
Journal:  Curr Neuropharmacol       Date:  2011-12       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.